Page last updated: 2024-12-11

sch 32615

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5486715
CHEMBL ID161885
SCHEMBL ID391211
MeSH IDM0172609

Synonyms (22)

Synonym
sch-32615
(n-(1-carboxy-2-phenyl)ethyl)phenylalanyl-b-alanine
beta-alanine, n-(n-(1-carboxy-2-phenylethyl)-l-phenylalanyl)-, (s)-
sch 32615
(2s)-2-[[(2s)-1-(2-carboxyethylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-phenylpropanoic acid
CHEMBL161885 ,
2-[1-(2-carboxy-ethylcarbamoyl)-2-phenyl-ethylamino]-3-phenyl-propionic acid
bdbm50016765
unii-lt9yzc71vz
83861-02-3
lt9yzc71vz ,
DTXSID90232752
sch32615
SCHEMBL391211
.beta.-alanine, n-((1s)-1-carboxy-2-phenylethyl)-l-phenylalanyl-
n-((1s)-1-carboxy-2-phenylethyl)-l-phenylalanyl-.beta.-alanine
MS-26324
HY-106887
(s)-2-(((s)-1-((2-carboxyethyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-3-phenylpropanoic acid
CS-0026836
STARBLD0024254
AKOS040749447

Research Excerpts

Overview

SCH 32615 is a novel inhibitor of the enzyme, neutral endopeptidase (NEP)

ExcerptReferenceRelevance
"SCH 32615 is a novel inhibitor of the enzyme, neutral endopeptidase (NEP, E.C. "( The neutral endopeptidase-24.11 (enkephalinase) inhibitor, SCH 32615, increases dopamine metabolism in the nucleus accumbens of the rat.
Biggio, G; Giorgi, O; Ongini, E; Pibiri, MG; Trampus, M, 1991
)
1.97

Toxicity

ExcerptReferenceRelevance
"The analgesic and acute central nervous system (CNS) side effect potential of the enkephalinase inhibitor SCH 32615 (N-[L-(1-carboxy-2-phenyl)ethyl]-L-phenyl-alanine-beta-alanine) were evaluated after IV administration to mice, rats and squirrel monkeys."( Analgesic and acute central nervous system side effects of the intravenously administered enkephalinase inhibitor SCH 32615.
Chipkin, RE; Coffin, VL, 1991
)
0.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NeprilysinOryctolagus cuniculus (rabbit)IC50 (µMol)0.02000.00040.66118.2000AID147211
Angiotensin-converting enzymeRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00090.33223.0300AID37965
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID37965Compound was evaluated for the ability to inhibit Angiotensin I converting enzyme in rat1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Carboxyalkyl dipeptides with atrial natriuretic factor potentiating and antihypertensive activity.
AID147211Compound was evaluated for the ability to inhibit neutral endopeptidase purified from rabbit kidney1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Carboxyalkyl dipeptides with atrial natriuretic factor potentiating and antihypertensive activity.
AID37863Compound was administered subcutaneously to spontaneously hypertensive rats (SHR) and evaluated for the ability to potentiate atrial natriuretic factor (ANF)1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Carboxyalkyl dipeptides with atrial natriuretic factor potentiating and antihypertensive activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.13)18.7374
1990's30 (93.75)18.2507
2000's1 (3.13)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.68 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index6.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.25%)5.53%
Reviews1 (3.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (90.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]